Big Gain For Genprex, Inc.

Fri, Feb 14, 2020 at 05:30 PM

Genprex, Inc. (GNPX:NASDAQ) soared at $4.28, representing a gain of 56.2%. On Thu 13 Feb 20, GNPX:NASDAQ hit a New 2-Week High of $2.74. The stock appeared on our News Catalysts scanner on Tue 11 Feb 20 at 02:17 PM in the 'AGREEMENT' category. From Fri 24 Jan 20, the stock recorded 57.14% Up Days and 46.67% Green Days

About Genprex, Inc. (GNPX:NASDAQ)

Genprex Inc is a clinical stage gene therapy company. It develops therapies that carry cancer-fighting genes. Its initial product candidate is Oncoprex.

Top 10 Gainers:

Summer Infant, Inc. (SUMR:NASDAQ), 288.03%
Genprex, Inc. (GNPX:NASDAQ), 56.2%
BioXcel Therapeutics, Inc. (BTAI:NASDAQ), 55.01%
Zosano Pharma Corporation (ZSAN:NASDAQ), 38.55%
Digital Ally, Inc. (DGLY:NASDAQ), 34.89%
PAVmed Inc. (PAVM:NASDAQ), 32.26%
ImmunoGen, Inc. (IMGN:NASDAQ), 26.87%
Huitao Technology Co., Ltd. (HHT:NASDAQ), 24.18%
The Chemours Company (CC:NYSE), 23.53%
scPharmaceuticals Inc. (SCPH:NASDAQ), 21.86%